$1.89
8.05% today
NYSE, Apr 03, 06:41 pm CET
ISIN
US02157Q1094
Symbol
ANRO
Sector
Industry

Alto Neuroscience Stock price

$2.05
-1.09 34.71% 1M
-7.96 79.52% 6M
-2.18 51.54% YTD
-12.06 85.47% 1Y
-13.95 87.19% 3Y
-13.95 87.19% 5Y
-13.95 87.19% 10Y
NYSE, Closing price Wed, Apr 02 2025
+0.03 1.49%
ISIN
US02157Q1094
Symbol
ANRO
Sector
Industry

Key metrics

Market capitalization $55.50m
Enterprise Value $-95.79m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 1.94
P/B ratio (TTM) P/B ratio 0.37
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-68.61m
Free Cash Flow (TTM) Free Cash Flow $-49.50m
Cash position $168.23m
EPS (TTM) EPS $-2.28
P/E forward negative
Short interest 17.69%
Show more

Is Alto Neuroscience a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Alto Neuroscience Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Alto Neuroscience forecast:

6x Buy
75%
2x Hold
25%

Analyst Opinions

8 Analysts have issued a Alto Neuroscience forecast:

Buy
75%
Hold
25%

Financial data from Alto Neuroscience

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.57 0.57
-
-
-0.57 -0.57
-
-
- Selling and Administrative Expenses 20 20
-
-
- Research and Development Expense 47 47
-
-
-68 -68
-
-
- Depreciation and Amortization 0.57 0.57
-
-
EBIT (Operating Income) EBIT -69 -69
-
-
Net Profit -61 -61
-
-

In millions USD.

Don't miss a Thing! We will send you all news about Alto Neuroscience directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Alto Neuroscience Stock News

Neutral
Business Wire
14 days ago
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the full-year ended December 31, 2024, and highlighted recent progress across its pipeline of clinical-stage pro...
Neutral
Business Wire
about one month ago
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company management team will present at the following upcoming investor conferences and events in March: TD Cowe...
Neutral
Business Wire
about one month ago
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that the U.S. Patent and Trademark Office has granted U.S. Patent Number 12,226,375, with method claims pertaining to treatment of ma...
More Alto Neuroscience News

Company Profile

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Los Altos, CA.

Head office United States
CEO Amit Etkin
Employees 76
Founded 2019
Website www.altoneuroscience.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today